Core Viewpoint - The company, Maipu Medical, reported significant growth in revenue and net profit for the first half of 2025, driven by its focus on core business and innovative product development in the neurosurgery field [1] Financial Performance - The company achieved operating revenue of 158 million yuan, a year-on-year increase of 29.28% [1] - The net profit attributable to shareholders reached 47.3 million yuan, up 46.03% year-on-year [1] - Basic earnings per share were reported at 0.71 yuan [1] Product Development - The company launched a new generation of artificial dura mater (spinal) patch, "Ruikang," which enhances flexibility and ease of use in clinical settings [2] - Sales revenue from dura mater products reached 71.4 million yuan, a growth of 3.24% compared to the previous year [2] - The craniofacial repair and fixation system generated sales of 44.3 million yuan, reflecting a 24.69% increase year-on-year [2] Market Expansion - The company has established partnerships with over 800 distributors and its products are available in more than 2,000 hospitals domestically, with a market presence in over 100 countries and regions globally [1] - Domestic revenue was 119.7 million yuan, growing by 23.84%, while international revenue reached 38.1 million yuan, increasing by 50.96% [3] R&D and Innovation - The company is focused on expanding its product applications from neurosurgery to multiple departments, with ongoing R&D efforts [4] - The absorbable regenerated oxidized cellulose hemostatic product is one of the few domestically industrialized products, aiming to break the long-standing import monopoly [3] - The hard dura mater medical glue received MDR certification, allowing for legal sales in EU markets, marking a significant achievement in the company's international strategy [4]